DBV Technologies (NASDAQ:DBVT) Stock Rating Lowered by Wall Street Zen

DBV Technologies (NASDAQ:DBVT) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other equities analysts also recently commented on DBVT. Citizens Jmp upped their target price on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a report on Wednesday, December 17th. Guggenheim reaffirmed a “buy” rating and issued a $51.00 target price (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Finally, HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research note on Thursday, December 18th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, DBV Technologies has an average rating of “Moderate Buy” and an average price target of $35.38.

DBV Technologies Price Performance

Shares of NASDAQ:DBVT opened at $21.61 on Friday. The stock’s 50-day moving average is $18.47 and its 200 day moving average is $14.02. The company has a market cap of $867.86 million, a PE ratio of -4.18 and a beta of -0.98. DBV Technologies has a 1 year low of $3.80 and a 1 year high of $26.18.

Insider Buying and Selling

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57. Following the sale, the insider owned 7,303,369 shares in the company, valued at approximately $30,601,116.11. This represents a 15.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.44% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund purchased a new stake in shares of DBV Technologies in the third quarter worth $34,000. GAMMA Investing LLC boosted its stake in DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares in the last quarter. Two Sigma Investments LP purchased a new stake in DBV Technologies during the 3rd quarter valued at about $167,000. Citadel Advisors LLC bought a new stake in DBV Technologies during the 3rd quarter valued at about $220,000. Finally, DLD Asset Management LP purchased a new position in DBV Technologies in the third quarter worth about $250,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.